MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 202841 | Name: TAS-109
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TAS-109, also known as DFP-10917 and CNDAC, is an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Nucleoside analogue TAS-109 is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.

Chemical Structure

TAS-109
TAS-109
CAS#135598-68-4 (free base)

Theoretical Analysis

MedKoo Cat#: 202841

Name: TAS-109

CAS#: 135598-68-4 (free base)

Chemical Formula: C10H12N4O4

Exact Mass: 252.0859

Molecular Weight: 252.23

Elemental Analysis: C, 47.62; H, 4.80; N, 22.21; O, 25.37

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
50mg USD 650.00 2 Weeks
100mg USD 1,000.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
135598-68-4 (free base) 134665-72-8 (HCl)
Synonym
TAS109; TAS109; TAS 109; DFP-10917; DFP 10917; DFP10917; CNDAC; Radgocitabine
IUPAC/Chemical Name
(2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile
InChi Key
DCYBPMFXJCWXNB-JWIUVKOKSA-N
InChi Code
InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1
SMILES Code
N#C[C@@H]1[C@H](N2C=CC(N)=NC2=O)O[C@H](CO)[C@H]1O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
TAS-109 is a novel deoxycitidine analogue with unique mechanism of action. Brief exposure to high concentrations of TAS-109 inhibits DNA polymerase resulting in S-phase arrest, while prolonged exposure to TAS-109 at low concentration causes DNA fragmentation, G2/M phase arrest and apoptosis. TAS-109 demonstrated activity in tumor xenografts resistant to other deoxycitidine analogs. CI of TAS-109 is feasible and well tolerated with myelosuppression as main DLT. The recommended doses are 2 mg/m²/day and 3 mg/m²/day on the 14-day and 7-day CI schedules respectively. Preliminary activity was suggested. PD data demonstrate biological activity at the tested doses. see http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/2577.    

Preparing Stock Solutions

The following data is based on the product molecular weight 252.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
 1: Reeves MD. Increase in quality, but not quantity, of clinical trials in acute pain: 1992 versus 2007. Anesth Analg. 2009 Nov;109(5):1656-8. PubMed PMID: 19843804. 2: Taş A, Yağız R, Koçyiğit M, Karasalihoğlu AR. Primary nasopharyngeal tuberculosis. Kulak Burun Bogaz Ihtis Derg. 2009 Mar-Apr;19(2):109-11. PubMed PMID: 19796011. 3: Lubkowska A, Szygula Z, Klimek AJ, Torii M. Do sessions of cryostimulation have influence on white blood cell count, level of IL6 and total oxidative and antioxidative status in healthy men? Eur J Appl Physiol. 2010 May;109(1):67-72. Epub 2009 Sep 25. PubMed PMID: 19779735. 4: Cirit U, Bacinoglu S, Taş M, Demir K, Baş A, Ak K, Ileri IK. Evaluation of short estrus synchronization methods in dairy cows. Anim Reprod Sci. 2008 Dec;109(1-4):65-76. Epub 2007 Dec 28. PubMed PMID: 18276087. 5: Schaefer A, Matthess H, Pfitzer G, Köhle K. [Mental health and performance of medical students with high and low test anxiety]. Psychother Psychosom Med Psychol. 2007 Jul;57(7):289-97. Epub 2007 Mar 14. German. PubMed PMID: 17357900. 6: Seal JA, Doyle Z, Burgess JR, Taylor R, Cameron AR. Iodine status of Tasmanians following voluntary fortification of bread with iodine. Med J Aust. 2007 Jan 15;186(2):69-71. PubMed PMID: 17223766. 7: Ham BJ, Lee MS, Lee YM, Kim MK, Choi MJ, Oh KS, Jung HY, Lyoo IK, Choi IG. Association between the catechol O-methyltransferase Val108/158Met polymorphism and alexithymia. Neuropsychobiology. 2005;52(3):151-4. PubMed PMID: 16127282. 8: Tan CF, Piao YS, Kakita A, Yamada M, Takano H, Tanaka M, Mano A, Makino K, Nishizawa M, Wakabayashi K, Takahashi H. Frontotemporal dementia with co-occurrence of astrocytic plaques and tufted astrocytes, and severe degeneration of the cerebral white matter: a variant of corticobasal degeneration? Acta Neuropathol. 2005 Mar;109(3):329-38. Epub 2004 Nov 12. PubMed PMID: 15841415. 9: Stott K, Desmerger C, Holford P. Relationship among Lepista species determined by CAPS and RAPD. Mycol Res. 2005 Feb;109(Pt 2):205-11. PubMed PMID: 15839104. 10: Hong CC, Choi JW, Ahn CH. A novel in-plane passive microfluidic mixer with modified Tesla structures. Lab Chip. 2004 Apr;4(2):109-13. Epub 2004 Feb 10. PubMed PMID: 15052349. 11: Doyle Z, Seal J. The tasmanian iodine monitoring program in schools. Asia Pac J Clin Nutr. 2003;12 Suppl:S14. PubMed PMID: 15023603. 12: Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 2003;3(3):339-53. Review. PubMed PMID: 12570767. 13: Lichtenberg P, Bachner-Melman R, Gritsenko I, Ebstein RP. Exploratory association study between catechol-O-methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability. Am J Med Genet. 2000 Dec 4;96(6):771-4. PubMed PMID: 11121178. 14: Newaz MA, Nawal NN. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exp Hypertens. 1999 Nov;21(8):1297-313. PubMed PMID: 10574414. 15: Solomon HM, Mullins RE, Lyden P, Thompson P, Hudoff S. The diagnostic accuracy of bedside and laboratory coagulation: procedures used to monitor the anticoagulation status of patients treated with heparin. Am J Clin Pathol. 1998 Apr;109(4):371-8. PubMed PMID: 9535388. 16: Carmi R, Barbash A, Mares AJ. The thoracoabdominal syndrome (TAS): a new X-linked dominant disorder. Am J Med Genet. 1990 May;36(1):109-14. PubMed PMID: 2139758. 17: Lominadze DG, Shinkarenko VS, Mamisashvili VA. [Study of the trajectory of erythrocyte movement in microvessels using a method of automatic image analysis]. Biull Eksp Biol Med. 1990 Apr;109(4):343-4. Russian. PubMed PMID: 2386823. 18: Loiselle CG, Dawson C. Toronto Alexithymia Scale: relationships with measures of patient self-disclosure and private self-consciousness. Psychother Psychosom. 1988;50(2):109-16. PubMed PMID: 3255977. 19: Tas K. [Diagnostic problems in a patient with hematuria]. Ned Tijdschr Geneeskd. 1965 Dec 18;109(51):2455-8. Dutch. PubMed PMID: 5852449.